Bausch Health (BHC) Q3 2026 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Oct. 28, 2026

CALL PARTICIPANTS

• Chief Executive Officer - Thomas J. Appio
• Chief Financial Officer - Jean-Jacques Charhon
• Chief Medical Officer and Head of Research and Development - Jonathan Sadeh
• Vice President of Investor Relations - Garen Sarafian

TAKEAWAYS

• Consolidated Revenues -- $2.94 billion, representing a 10% increase on a reported basis and 8% on an organic basis compared with the prior year period.
• Bausch Health (excluding Bausch + Lomb) Adjusted EBITDA -- $1.022 billion, marking the first time this metric has exceeded the 1 billion milestone in a single quarter.
• Net Debt Reduction -- $521 million during the third quarter, driven by operational performance and strong cash generation.
• Salix Segment Revenue -- $831 million, an increase of 16% primarily due to demand and pricing for Xifaxan.
• Full Year 2026 Revenue Guidance (excluding Bausch + Lomb) -- $5.525 billion to $5.625 billion, reflecting an increase of $150 million at the midpoint of the range.
• Full Year 2026 Adjusted EBITDA Guidance (excluding Bausch + Lomb) -- $3.225 billion to $3.275 billion, representing a 13% increase versus 2025 at the midpoint.
• Full Year 2026 Adjusted Cash Flow from Operations Guidance (excluding Bausch + Lomb) -- $1.6 billion to $1.675 billion, representing a 29% increase year over year at the midpoint.
• Xifaxan Revenue Growth -- 16% year over year, supported by favorable net realized pricing and a 1.8% increase in total retail prescriptions excluding Medicaid.
• Solta Medical Revenue -- $165 million, an increase of 18% on a reported basis aided by the integration of the full-service distributor in China.
• International Segment Revenue -- $299 million, growing 4% on an organic basis with contributions from all major geographies including Canada and EMEA.
• Diversified Segment Revenue -- $271 million, an increase of 5% driven by double-digit growth in the dermatology business.
• Adjusted Earnings per Diluted Share -- $1.77, compared with $1.16 in the prior year period, representing a 53% increase.
• Cash on Hand -- $2 billion as of the end of the quarter, providing liquidity for early debt redemptions and open market repurchases.
• Xifaxan Q4 Revenue Headwind -- 800 basis points of growth reduction, resulting from gross to net accrual adjustments in anticipation of new Medicare pricing.
• Xifaxan Q4 EBITDA Headwind -- 1,400 basis points of growth reduction, associated with the Medicare price change effective Jan. 1, 2027.
• Thermage FLX Global Growth -- 21% for the quarter, supporting the overall performance of the medical aesthetics portfolio.
• Fraxel and Clear + Brilliant Touch Growth -- 52% and 49% respectively, reflecting gains in the aesthetics business off modest bases.
• New-to-Brand Patients -- 1.8 thousand sequential increase for Xifaxan, indicating continued vitality and demand for the product.
• Bedoyecta Organic Growth -- 28% in Latin America, where it remains a leading brand within the region's portfolio.
• Net Debt Reduction Year-to-Date -- more than $1 billion, reflecting progress toward strengthening the balance sheet since the start of the year.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

• Charhon stated, "we will need to adjust the gross to net accrual associated with our channel inventory in anticipation of the new Xifaxan price to Medicare taking effect on January 1, 2027," which is expected to negatively impact fourth-quarter growth.
• Appio noted that in the China market, "the market has softened a little bit in terms of the consumer confidence and the spending," creating organic revenue pressure for Solta Medical.

SUMMARY

Bausch Health Companies Inc. (NYSE:BHC) reported its fourth consecutive quarter of year-over-year revenue and adjusted EBITDA growth for its core business excluding Bausch + Lomb. Management highlighted a significant financial milestone as quarterly adjusted EBITDA for the healthcare segment exceeded 1 billion for the first time. The company focused on debt reduction, utilizing strong operational cash flow to lower net debt by more than $500 million in the third quarter. Despite anticipated headwinds in the final quarter related to Medicare pricing adjustments for Xifaxan, the company raised its full-year guidance for revenue, adjusted EBITDA, and cash flow from operations. Strategic priorities remain centered on optimizing the commercial portfolio, advancing the internal R&D pipeline, and evaluating selective business development opportunities.

• CEO Thomas Appio emphasized his dual commitment to both organizations while serving as the interim leader of Bausch + Lomb.
• The larsucosterol Phase 3 program for alcohol-associated hepatitis remains on schedule for a targeted approval in 2029.
• Charhon estimated that the net impact of all puts and takes related to Medicare pricing in 2027 will be "around $400 million to $500 million year over year."
• Management is pursuing early redemptions of 2027 notes and up to $100 million of open market repurchases of public debt to optimize capital allocation.
• The international business achieved its 15th consecutive quarter of organic revenue growth in the EMEA region, supported by momentum in Poland and Hungary.
• The company authorized a $50 million share repurchase program primarily to offset dilution from the anticipated vesting of management equity awards in 2027.

INDUSTRY GLOSSARY

• Xifaxan: A gastrointestinal antibiotic used to treat irritable bowel syndrome with diarrhea and hepatic encephalopathy.
• Solta Medical: A segment of Bausch Health specializing in medical aesthetic devices for skin tightening and resurfacing.
• Larsucosterol: An epigenetic drug candidate currently in Phase 3 clinical trials for the treatment of alcohol-associated hepatitis.
• Adjusted EBITDA: A non-GAAP financial measure that excludes interest, taxes, depreciation, and amortization to reflect core operational performance.
• Organic Revenue: A measure of revenue growth that excludes the impact of foreign currency fluctuations, acquisitions, and divestitures.
• Thermage FLX: A non-invasive skin tightening treatment utilizing radiofrequency technology.
• Gross to Net Accrual: An accounting adjustment reflecting the difference between gross sales and net revenue after accounting for rebates, discounts, and returns.

Full Conference Call Transcript

Operator: Greetings, and welcome to the Bosch Health Third Quarter 26 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Garen Sarafian, Head of Investor Relations. Please go ahead.

Garen Sarafian: Good afternoon, and welcome to Bausch Health's third quarter 26 Earnings Conference Call. Name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas J. Appio, Chief Executive Officer; Jean-Jacques Charhon, Chief Financial Officer; and Jonathan Sadeh, Chief Medical Officer and Head of Research and Development. Before we begin, I would like to remind you that today's presentation contains forward looking information. Please take a moment to review the forward looking statements disclaimer at the beginning of the slides accompanying this presentation. It contains important information. Actual results may differ materially from those expressed or implied in these forward looking statements and you should not place undue reliance on them.

Please also refer to our SEC filings and our filings with the Canadian Securities Administrators for a discussion of certain risk factors that could cause actual results to differ materially from expectations. We use non GAAP financial measures to help investors better understand our operating performance. These non GAAP measures may not be comparable to similarly titled measures used by other companies and should be considered in addition to and not as a substitute for measures calculated in accordance with GAAP. Reconciliations to our non GAAP measures are included in the appendix of the slides accompanying this presentation which are also available on Bausch Health's Investor Relations website. Finally, financial guidance in this presentation is effective as of today only.

Do not undertake any obligation to update guidance. Our discussion today, Wednesday, October 28, will focus on Bausch Health excluding Bausch and Lomb. However, we will briefly comment on Bausch and Lomb's results announced this morning. We will refer to year over year comparisons with the same period last year unless otherwise noted. With that, I will turn the call over to our CEO, Tom Appio. Tom?

Thomas J. Appio: Thank you, Garen, and thank you to everyone joining us today. Before I discuss our third quarter results, I want to briefly address my recent appointment at interim CEO of Bausch and Lomb. I am honored and energized to serve as interim CEO. Having spent a good part of my career with the company, I have developed a deep understanding of their business, markets, products, and most importantly, the exceptional global team who drive their success. Having said that, I want to reiterate that I remain fully committed to Bausch Health and all its stakeholders. I am proud of our 7 thousand colleagues around the world and all that we continue to achieve together.

Both companies have experienced teams and well defined operating priorities. Allowing us to remain focused on execution across each business. Turning now to Bausch Health, we delivered another solid quarter, extending our record to 4 consecutive quarters of year over year revenue and adjusted EBITDA growth for Bausch Health excluding Bausch and Lomb. For the first time, we exceeded 1 billion in quarterly adjusted EBITDA marking another important milestone for our company. We generated 1 of our highest adjusted quarterly cash flow from operations since the IPO of Bausch + Lomb. Building on the progress achieved during the first half of the year, this cash generation enabled us to reduce our net debt by more than $500 million.

Our execution through the first 9 months gives us the confidence to again raise our full-year 2026 guidance for revenue adjusted EBITDA and adjusted cash flow from operations. More importantly, the consistency of our performance continues to demonstrate the strength of our strategy, the discipline of our operations and the accountability that we have built throughout the organization. Let me start with a few highlights from the quarter. Within Salix, revenue increased 16% driven by net realized pricing and increased volume within the channels we serve today. This is the 17th consecutive quarter of growth for Salix. Our international business grew mid-single-digit on both reported and organic basis, Canada achieved 6% growth with continued momentum in promoted products.

EMEA, delivered its 15th consecutive quarter of organic revenue growth supported by several markets including Poland and Hungary. Latin America, also delivered positive underlying growth in both established brands and new products. Finally, Solta delivered another quarter of double digit reported revenue growth supported by its leaning aesthetics portfolio and the successful integration of our China distributor. This quarter, Thermage FLX grew 21% globally while Fraxel and Clear + Brilliant Touch grew 52%, 49% respectively, off more modest basis. These results demonstrate the breadth of our global organization and the progress across multiple segments markets and products. While we are pleased with our third quarter results, the greater achievement is our ability to sustain this level of performance over time.

We have greater discipline, accountability and consistency in our execution across the organization. The result is 14 consecutive quarters of revenue and adjusted EBITDA growth across a diverse portfolio of businesses and markets. This performance reflects a consistent set of management that guide how we operate the business every day. The first principle is profitable revenue growth. With the objective of delivering long term value creation. Our last 12 months revenue provides a good measure of that progress. The metric has grown every quarter since year-end 2023, resulting in approximately 24% growth cumulatively over that period.

Throughout our businesses, we are optimizing the operating levers available to us within Salix, We are maximizing performance throughout the product life cycle supported by customer insights engine and strong commercial capabilities. At Solta, we are improving commercial execution while investing in innovation and R&D to support future growth. In international, we are strengthening the portfolio through targeted product launches including important markets such as Mexico and Poland. For all our businesses, the objective is the same. Disciplined commercial focus that drives sustainable profitable growth. The second principle is disciplined resource allocation and operating leverage. We make targeted strategic investments where we see the potential for long term returns.

At the same time, we continuously evaluate our infrastructure and pursue productivity throughout the organization. This combination of profitable growth and resource discipline has contributed to approximately 740-basis-points of last 12 months adjusted EBITDA margin expansion compared with 2023. The third principle is cash generation. Our operating performance has translated into growing cash flow from our existing businesses this has supported a reduction in net debt every quarter since the fourth quarter of 23. With this quarter representing 1 of the largest quarterly net debt reductions since the IPO of Bausch and Lomb. These core principles continue to guide our actions and priorities across the organization.

Our third quarter performance is further evidence that consistent execution can create sustainable value across the business. With that, I will turn the call over to JJ for a more detailed review of our financial results and updated guidance. JJ?

Jean-Jacques Charhon: Thank you, Tom. Let's start with our consolidated non GAAP financial results for the third quarter, which you will find starting on Page 12. Revenues were $2.941 billion, a 10% increase on a reported basis and 8% on an organic basis compared to the same period a year ago. Adjusted gross margin was 75% which was 32 basis points higher year over year. Adjusted EBITDA was $1.305 billion, an increase of $319 million or 32% year-over-year. Finally, adjusted cash flow from operations was $782 million, an increase of $274 million or 54% year-over-year. Moving now to the performance of Bausch Health excluding Bausch and Lomb for the third quarter starting on Page 14.

As Tom indicated earlier, we had announced outstanding third quarter. The highlights for the quarter were as follows. Revenues were $1.566 billion, a 12% increase when compared to the third quarter of 2025. Adjusted EBITDA was $1.022 billion, our strongest quarterly performance since the IPO of B&L. Finally, adjusted cash flow from operations was $539 million, an increase of $192 million year over year. These results reflect broad based operating performance across the whole portfolio. While the largest drivers of growth remain Salix all segments grew revenue and segment profits in the quarter a rare feat we are very proud of. Moving now to our third quarter performance by segment, starting with Salix on Page 15.

Salix had another quarter of double digit growth for both revenue and segment profit. Revenues were $831 million, an increase of $115 million This outstanding performance was primarily driven by Xifaxan which grew 16% year over year, thanks to favorable net realized pricing and continued solid demand as evidenced by total retail prescriptions excluding Medicaid which grew 1.8%. Separately, our quarterly new to brand patients grew by 1.8 thousand sequentially reflecting the continued vitality of Xifaxan today. Please note that volume growth in Q3 was also boosted by an increase in channel inventory. Now moving to the international segments.

Revenues in the third quarter were $299 million, which was up 4% on an organic basis compared to the third quarter of last year. Growth was supported by contribution from all major geographies, reflecting the broad based performance of our international portfolio. Here are a few highlights by region. EMEA continued its streak in sales growth up 3% organically, now delivering a remarkable 15th consecutive quarter of organic revenue growth. Special mentions go to Poland and Hungary, which grew respectively 7%, 32%. LATAM continued its return to growth fueled by our top 10 products growing 18% organically thanks to an outstanding performance of our largest brand Bedoyecta which was up 28% on an organic basis.

Canada, also returned to growth with organic revenue up 7%, and promoted product delivering another quarter of double digit gains led by Rialtris and Cabtreo. Now moving to Page 17 for a review of our Solta Medical segments. Solta delivered solid revenue in the quarter of $165 million, an increase year-over-year of 18% on a reported basis. Asia Pacific continued to lead in reported growth with China and Taiwan increasing 66%, 23% respectively. Korea, was relatively flat despite continued growth through its consumables which were up 18% year-over-year.

Organic revenue declined 4% for the quarter reflecting a different revenue phasing for the first 9 months versus what we experienced in 2025 which was much more uneven and driven by the volatility of tariffs on US imported goods. On a year to date basis, Solta has grown revenues 34% on a reported basis and 8% on an organic basis which we believe is a more accurate representation of the strong performance we have consistently seen from Solta in 2026. Turning now to our diversified segments, which you will find on page 18. Revenues were $271 million, an increase of 5% compared to the same period a year ago.

Revenue growth was primarily driven by double digit growth in dermatology thanks to favorable net realized pricing. Finally, Bausch + Lomb revenues were $1.375 billion, up 7% on an organic basis compared to the same period last year. Now turning our focus to our cash flow and balance sheet. Our cash flow performance continues to be above expectations primarily thanks to our adjusted EBITDA growth which is tracking well ahead of plan and external guidance. Consequently, we were able to reduce our net debt by $521 million during the quarter. Since the beginning of the year, we have reduced our net debt by more than $1 billion. Which has been great progress.

We now have $2 billion of cash on hand and are looking at ways for optimizing our capital allocation. Which will include early redemptions of our 2027 notes and up to $100 million of open market repurchases of some of our public debt. Separately, we are announcing a $50 million share repurchase program primarily aimed at offsetting the dilution coming from the anticipated vesting of management equity awards in 2027. Before I hand it over to Tom, let me close with our full year guidance, which you will find on Page 22.

Not surprisingly, the strength of our result in Q3 is allowing us to raise our 2026 full year guidance across all metrics for the second quarter in a row. More specifically, we are increasing the midpoint of our full year guidance by $150 million for revenue approximately $190 million for adjusted EBITDA and $200 million for adjusted cash flow from operations. The new full year guidance stands now as follows. Revenue is expected to be between $5.525 billion and $5.625 billion the midpoint of that range translates to an 8% increase year over year. Adjusted EBITDA is now expected to be between $3.225 billion and $3.275 billion the midpoint of that range represents a 13% increase versus 2025.

Finally, we now anticipate adjusted cash flow from operations to be between $1.6 billion and $1.675 billion the mid point of that range translates to a 29% increase year over year. Even with this new guidance, we will face headwinds in Q4 as performance is expected to be impacted by 2 primary drivers. First and foremost, as we have communicated consistently we will need to adjust the gross to net accrual associated with our channel inventory in anticipation of the new Xifaxan price to Medicare taking effect on January 1, 2027. This element alone represents 800 basis points of revenue growth reduction and 1.4 thousand basis points of adjusted EBITDA growth reductions for the quarter.

Second, we have assumed in our revised guidance some normalization of the Xifaxan channel inventory. That driver could represent at least another 300 basis points of growth reduction in Q4 and 500 basis points of adjusted EBITDA for the quarter. In summary, Q3 was another outstanding quarter of performance across all segments following an equally impressive first half. We are raising our full year guidance for the second time this year and look forward to closing out the year operationally on a strong note. I will now hand it back to Tom.

Thomas J. Appio: Thank you, JJ. As JJ outlined, we delivered strong results through the first 9 months of 2026, with revenue and adjusted EBITDA increasing by 14%, 26% respectively. Looking ahead, our business priorities remain clear First, drive peak performance across our portfolio. Second, enhance the value of our portfolio through consistent organic growth and operational excellence initiatives. Third, build a sustainable pipeline of future growth opportunities organically and inorganically through business development And fourth, maximize the value of Bausch and Lomb for shareholders. These priorities provide a clear framework for how we intend to create value, maximize the performance of the assets we have today, strengthen those businesses through disciplined execution and use our capabilities to create new avenues for growth.

That opportunity extends across our portfolio Beyond Xifaxan, we have established businesses with many of the capabilities to support continued growth. Let me highlight several examples. EMEA, is approaching 4 consecutive years of quarterly organic revenue growth. It is a branded generics business serving hospital and retail channels, with no single product representing more than 8% of revenue. Our established commercial infrastructure particularly in Poland, is well positioned to support additional assets including those sourced through business development. In Latin America, our business consists predominantly of a branded generics portfolio with no meaningful loss of exclusivity exposure. Mexico remains our largest market. With reach across 10 additional Central American countries.

We see additional potential within the cardiometabolic therapies while Bedoyecta remains a leading and highly recognized brand in the region. In Canada, our promoted portfolio continues to grow at a double-digit rate supported by established commercial capabilities This infrastructure provides a scalable foundation for future pipeline opportunities across the country. In The United States, our dermatology franchise is expected to strengthen as a result of optimizing our commercial deployment. Finally, Solta gives us a differentiated global medical aesthetics platform with premium brands, a broad global portfolio, and recurring revenue from consumables across its installed base. Each of these businesses is different.

But they share a common foundation established platforms, commercial capabilities, and local expertise that can support organic growth as well as additional assets over time. Together, these businesses demonstrate the breadth of our portfolio, the value of our commercial infrastructure, and the opportunities available to us through operational excellence. They also provide capabilities we can build upon as we invest in the future. A key part of that investment is building our pipeline. We are pursuing this in 2 ways. Advancing innovation internally and selectively adding opportunities through business development.

Within R&D, our Phase 3 program for larsucosterol in alcohol associated hepatitis continues to progress well and remain on track toward our goal of approval in 2029, subject to the successful completion of clinical development and regulatory review. At the same time, we continue to look externally for opportunities to strengthen our pipeline. Business development remains a high priority and we are actively evaluating opportunities where our existing expertise and commercial capabilities can add value. Particularly across hepatology, gastroenterology, dermatology and neuroscience. Our approach remains disciplined and strategic.

We are focused on opportunities that complement our existing businesses, leverage capabilities, and have the potential to contribute to sustainable growth over time while remaining thoughtful about how these investments fit with our capital structure. In closing, 2026 is shaping up to be another strong year for Bausch Health. Our third quarter results build on the progress achieved during the first half, Based on that performance, we are again raising our full year guidance for revenue, adjusted EBITDA and adjusted cash flow from operations. Our priorities are well defined. We remain focused on operational excellence across our businesses making targeted investments in our portfolio, and pursuing opportunities that can create sustainable long term value.

Following the strong performance of the past 9 months, I want to take this opportunity to recognize and thank our colleagues around the world their continued dedication, accountability, and commitment has made a difference in our relentless drive to create better health outcomes for patients. We are entering the fourth quarter with solid momentum and confidence in the path ahead. With that, I will turn the call over to the operator so we can open the line for Q and A.

Operator: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, Thank you. Our first question is from Umer Raffat with Evercore ISI.

Umer Raffat: Congrats on all the data. A couple of points, if I may. Perhaps first, as I think about sort of the overall strategy going forward now, it seems increasingly that perhaps there may be possibly the 2 companies coming together, perhaps all under 1 roof, which technically is already the case, but maybe perhaps more formally, Could you speak to that, Tom, and sort of the general direction you see going forward? I just think that would be very, very helpful. Then also, JJ, could you clarify? I know you mentioned some points around Xifaxan's impact from IRA on top line. You mentioned it in Basis points growth.

Could you just say it in dollars? what is the dollar impact on revenue and the dollar impact on margin? Next year? And then finally, is there any you think about the powering for the phase 3 trial you structured in alcohol associated hepatitis, is there any possibility of an interim analysis that could come early which may not necessarily be in the street expectations? Thank you very much.

Thomas J. Appio: Hi, Umer. Thanks for the question. I will take the first part then JJ can take the second part, and then Jonathan can take the third part of your question. When we look at, you know, overall, from a BHC perspective, So, nothing has changed with what we have communicated in the past. And multiple objects. What I would say is I believe and we believe that Bausch + Lomb has a strong foundation and a very talented team. So, the way I see it is, we can do a little bit more. Yeah.

Jean-Jacques Charhon: So hi, Umer. How are you? So let me break down the impact of the new process CMS into 2 components. First component is the gross to net accrual I was referring to in my prepared remarks. That is anticipation of the price reduction happening in 2027. That amount is in excess of $100 million. We have provided some growth rate impact I think you can you can back into. The second part of your question is really the impact of that reduction following the IRA rebate. We have not provided any specific details. Suffice to say that, this information is public, So, when you look at the impact of that CMS rebate, you have to factor in 2 things.

Number 1, kind of the price increase, which is the starting point. And then the second part is the rebate down to a fixed price that was negotiated, in September 2024. What I think you can infer from the implicit guidance we provided for 2027, which is about $2.7 billion. Is that the net impact of all the puts and takes is around $400 million to $500 million year over year, which is a good order magnitude to consider when looking at the CMS impact. Okay.

Jonathan Sadeh: And I will take the third question about looking at the study, at the Phase III study, do an interim analysis. I think it is a good question. there is a few situations where we may want to do it. 1 is we are looking for futility, and we think that is not the case here. We feel pretty confident about the data from Phase 2, and we powered the study appropriately. The second, if you want to stop, I think that is what you are referring to, stop early and submit early. We think that is not really a possibility. We are only doing 1 study.

Remember, in this indication, it is a fairly short 1. it is only a 6-month treatment period. So we think we are we are on track to deliver complete the enrollment data, and submit that approval with assuming results will be replicated Phase 2 in 2029. We feel pretty confident about it and do not really see a need to do any interim analysis.

Thomas J. Appio: Operator, next question.

Operator: Our next question is from Douglas Miehm with RBC Capital Markets.

Douglas Miehm: Yes. Good afternoon, everyone. First question just has to do with Solta. And can management provide a bit more granularity on the organic demand trajectory in Asia Pacific ex-Shibo? And sustainability of, the Shibo integration benefits? And then maybe you could also comment related to that just on North America. It was also down and just curious about the softness there.

Thomas J. Appio: Sure, Douglas. Thanks for the question. I will. The I will take, the first part of it, and then, JJ might want to add to it. You know, when we look at the Solta business, organically and I look at year to date because it was a lot of in the prior year, given the tariff issue, given that we are going into the integration with Shibo. It was a little lumpy in the quarters as we looked at it in 2020 in 2025. So organically year-to-date, the total business is growing by 8%, and on a reported basis, including Shibo, 34%.

Now when I look at overall, if I look at the China market, the integration has gone very well. And the team is very confident as we move forward to 2027. I think the other issue that is China specific, it has to do with the market has softened a little bit in terms of the consumer confidence and the spending. So that has somewhat of an impact And then you look at some of the local competitors that are coming into the China market. Especially with. You know, in the skin tightening area, and it can be the local competitors that are China brands or the Korean competitors.

So that also has some sort of impact certainly in the early days but then usually we will flush out as you move forward. So we still believe that the China business organically will do. has a good future. When I look at Korea, we look at organically in Korea, 1 of the things there was the. You know, we had placed a lot of equipment in the prior years, and what we had said on previous calls that was not going to continue, it is a saturated. You know, it can be a very well-penetrated market. market. But clearly, if we are growing consumables, means the machines are being used and procedures are being done. We see growth there.

Overall in the US, it was basically flat to a. but volume was up When I take a look at there, you know, 1 of the focuses has been on the field execution and some of the work we are doing there to execute better at the field level. And there has been some competitor entrants as well. And, you know, the different price points and deal terms, can impact that in the short term. With that, I mean, JJ, have anything else to add?

Jean-Jacques Charhon: The only additional color I would provide to you is really, looking at Q4. Q4 is going to be a quarter for Solta that is going to have a lot of puts and takes. For a couple of reasons. Number 1, in anticipation of the acquisition of our distributor in China, were actually no sales recorded in November. And then the second thing is, December marked the first month where the increased price associated with the integration of our full service distributor was really benefiting the business.

And so on a reported basis, you will see we will return to strong growth in the fourth quarter, even on an organic basis I think the expectation is that we would be in the mid-single-digits for overall SALTA reflecting the very healthy dynamics we see in Korea. Both from a volume, but also from a price standpoint. Okay. Perfect.

Thomas J. Appio: Operator, next question. Yep. Yeah. Go ahead, Douglas. Go ahead.

Douglas Miehm: Oh, no. Yeah. I am I am just going to have a quick follow-up on that. Xifaxan litigation. There any visibility on the ruling timeline around the summary judgment motion? And on the Norwich II remand, has the FDA provided any indication of a timeline for the but-for cause Causation analysis?

Thomas J. Appio: Yeah. No problem. Help us out on those 2.

Jean-Jacques Charhon: Sure. Let's take the first 1 regarding the DC District Court. As you know, the DC District Court directed the FDA to devise a new framework. From. You know, right now, it has not gone back to the FDA yet, but I am assuming that is gonna happen shortly. And then we will have to wait and see in terms of what that timeline would be. When it comes to the other litigation, in terms of summary judgment, it has been heard, but we do not have anything at this time.

Douglas Miehm: Okay.

Thomas J. Appio: Thank you. All right, Douglas. Thank you.

Operator: Operator, next question. Thank you. There are no further questions at this time. I would like to hand the floor back over to Tom Appio, CEO, for any closing remarks.

Thomas J. Appio: Your as I said, we remain focused on executing with discipline strengthening our portfolio and delivering against the priorities we discussed today. I want to thank our colleagues around the world for everything they do on behalf of Bausch Health. We look forward to updating you again on our progress Thank you.

Operator: This does conclude today's conference call. We thank you again for your participation. You may now disconnect.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool recommends Bausch Health Companies. The Motley Fool has a disclosure policy.